REMARKS

Status of the Claims:

Claims 1-26 are pending. Claim 5 has been withdrawn from consideration by the Examiner as being drawn to non-elected invention. Claims 1-4 and 6-26 are currently under consideration. Applicants gratefully acknowledge that the Examiner has found claims 1-4 and 6-26 to be free of the prior art. Applicants further acknowledge gratefully that the Examiner has found that the Amendment filed on July 26, 2003 has obviated the enablement and indefiniteness rejection under 35 U.S.C. §112, as well as the new matter objection under 35 U.S.C. § 132.

Claims 1-3, 6, 10-12, 16-18 and 21-23 have been amended to more particularly point out the invention. Specifically, independent claims 1, 2, and 3 have been amended to recite that the immunoglobulin used in each of the respective methods comprises at least one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin derived from the III2R variable region and a portion of an immunoglobulin light chain of human origin derived from the H2F variable region. Dependent claims 6, 12, and 18 have been amended to recite that the antigen binding region of the immunoglobulin used in the claimed methods comprises one CDR of the variable region of the 3D1 antibody. Claims 10, 16, and 22 have been amended to recite that the immunoglobulin used in the claimed methods comprises a portion of an amino acid sequence of its variable region in common with a portion of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

amino acid sequence of the variable region of the III2R heavy chain. Claims 11, 17, and 23 have been amended to recite that the immunoglobulin used in the claimed methods comprises a portion of an amino acid sequence of its variable region in common with a portion of the amino acid sequence of the variable region of the H2F light chain. Support for these amendments is found in the specification at least on page 2, lines 1-23.

New claims 27-62 have been added. New independent claim 27, like claim 1, is drawn to a method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2 comprising contacting said second cell with an effective amount of a humanized immunoglobulin having binding specificity for B7-2, however, here the immunoglobulin comprises a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody and a heavy chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from the human III2R antibody.

New independent claim 34, like claim 2, is drawn to a method of inducing immunotolerance in a patient having a transplanted organ, tissue, cell, or the like comprising administering an effective amount of a humanized immunoglobulin having binding specificity for B7-2, however, here the immunoglobulin comprises a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody and a heavy chain which comprises one or more CDR's derived from an antibody of non-

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

human origin which binds to B7-2 and a framework region derived from the human III2R antibody.

New independent claim 41, like claim 3, is drawn to a method of reducing transplantation rejection in a patient having a transplanted organ, tissue, or cell, comprising administering a therapeutically effective amount of a humanized antibody having binding specificity for B7-2, however, here the immunoglobulin comprises a light chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from a human H2F antibody and a heavy chain which comprises one or more CDR's derived from an antibody of non-human origin which binds to B7-2 and a framework region derived from the human III2R antibody.

Dependent claims 28-33, 35-40, and 42-47 merely mirror dependent claims 6-11 and 24; 12-17 and 25; and 18-23 and 26 respectively. Dependent claims 48, 50, and 52 recite that the immunoglobulins used in the methods of claims 1, 2, and 3 respectively comprise a portion of an immunoglobulin light chain of human origin derived from the H2F (SEQ ID NOS: 26, 30) variable region which is the framework region. Similarly, dependent claims 49, 51 and 53 recite that the immunoglobulins used in the methods of claims 1, 2, and 3 respectively comprise a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region which is the framework region.

Dependent claims 54, 56 and 58 refer to the methods of claims 1, 2, and 3 respectively and recite that the antigen binding region comprises two CDRs of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

variable region of the 3D1 antibody. Similarly, dependent claims 55, 57 and 59 refer to claims 1, 2, and 3 respectively and recite that the antigen binding region comprises three CDRs of the variable region of the 3D1 antibody. It is well recognized that a variable region of an antibody has three CDR domains, and the specification notes this fact, as well, on page 8, lines 7-11, for example.

New independent claims 60, 61 and 62 merely replace "and" in paragraph b of claims 1, 2, and 3, respectively with "or."

Support for these claims is as put forth in the table below:

New Claim	Support
27	page 2, lines 1-23; page 5, lines 8-25; and page 10, lines 10-21
28	page 2, lines 1-23
29	page 2, line 11-page 3, line 10
30	page 2, lines 1-23 and page 3, lines 11-29
31	page 13, lines 3-15
32	page 13, lines 3-15
33	page 10, lines 10-15
34	page 2, lines 1-23; page 6, lines 20-29; and page 10, lines 10-21
35	page 2, line 11-page 3, line 10
36	page 2, line 11-page 3, line 10
37	page 2, lines 1-23
38	page 13, lines 3-15
39	page 13, lines 3-15
40	page 10, lines 10-15
41	page 5, lines 8-18 and page 10, lines 10-21
42	page 2, line 11-page 3, line 10
43	page 2, line 11-page 3, line 10
44	page 3, lines 11-29
45	page 13, lines 3-15
46	page 13, lines 3-15
47	page 10, lines 10-15
48	page 2, lines 1-23
49	page 2, lines 1-23
50	page 2, lines 1-23

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

New Claim	Support
51	page 2, lines 1-23
52	page 2, lines 1-23
53	page 2, lines 1-23
54	page 2, lines 1-23
55	page 2, lines 1-23
56	page 2, lines 1-23
57	page 2, lines 1-23
58	page 2, lines 1-23
59	page 2, lines 1-23
60	page 2, lines 1-23 and page 5, lines 8-11
61	page 2, lines 1-23 and page 6, lines 20-29
62	page 2, lines 1-23 and page 5, lines 8-18

The specification has also been amended to correct typographical errors. No new matter has been added.

Written Description Under 35 U.S.C. § 112 First Paragraph.

Claims 1-4 and 6-26 stand rejected under 35 U.S.C. §112, first paragraph for alleged lack of written description. The Office alleges that the specification as originally filed does not provide support for the claim terms: "at least a portion of an immunoglobulin of human origin derived from the III2R (SEQ ID NOS: 25, 29) and/or H2F (SEQ ID NOS: 26, 30) variable region." The Office specifically objects to the lack of reference to heavy and light chains with respect to the sequences. Without conceding the correctness of the rejection and for the sole purpose of expediting prosecution, Applicants have amended the claim to recite "a portion of an immunoglobulin heavy chain of human origin derived from the III2R (SEQ ID NOS: 25, 29) variable region and a portion of an immunoglobulin light chain of human origin

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

derived from the H2F (SEQ ID NOS: 26, 30) variable region." Applicants thus submit the rejection is obviated by this amendment.

CONCLUSION

In view of the foregoing remarks, Applicants respectfully request the reconsideration and reexamination of this application and the allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 20, 2004

By: E Stewart Mittler
E. Stewart Mittler
Reg. No. 50,316

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com